Virbac group
Virbac Group, a leading player in the global animal health industry, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1964, the company has established itself as a trusted provider of veterinary products and services, focusing on the health and well-being of companion animals and livestock. Virbac's core offerings include vaccines, pharmaceuticals, and nutritional products, all designed to enhance animal health and productivity. What sets Virbac apart is its commitment to research and development, ensuring innovative solutions tailored to the evolving needs of veterinarians and pet owners alike. With a strong market position, Virbac has achieved notable milestones, including a robust international presence and a diverse product portfolio that reflects its dedication to quality and efficacy in animal care.
DitchCarbon Score
How does Virbac group's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Virbac group's score of 31 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Virbac group's reported carbon emissions
In 2022, Virbac Group reported total carbon emissions of approximately 23,727,000 kg CO2e, all of which fall under Scope 1 emissions. This represents a notable increase from 2021, where emissions were about 20,814,000 kg CO2e. The company has also disclosed emissions data for previous years, with 2020 reporting approximately 21,007,000 kg CO2e in Scope 1 emissions and 2014 showing a broader emissions profile with Scope 1 at about 19,186,000 kg CO2e, Scope 2 at approximately 15,014,000 kg CO2e, and Scope 3 at about 6,818,000 kg CO2e. Despite the fluctuations in emissions, Virbac has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company’s emissions intensity, measured in relation to revenue, has shown a decreasing trend, with a GHG intensity of 0.237 in 2022 compared to 0.249 in 2020. Virbac's climate commitments and strategies remain somewhat vague, with no specific targets outlined for reducing their carbon footprint. As a player in the veterinary pharmaceutical industry, the company is positioned within a sector increasingly focused on sustainability and climate action, yet further clarity on their long-term climate strategy would be beneficial.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 19,186,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,014,000 | - | - | - |
| Scope 3 | 6,818,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Virbac group is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
